| Zhou, hu |
TE-ITP, NCT05583838: A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts |
|
|
| Completed | 4 | 157 | RoW | rhTPO, Recombinant human thrombopoietin, TPIAO, Eltrombopag, Eltrombopag olamine | Institute of Hematology & Blood Diseases Hospital, China, The Second Hospital of Hebei Medical University, Xijing Hospital, The Affiliated Hospital of Inner Mongolia Medical University, The Second Affiliated Hospital of Kunming Medical University, Second Affiliated Hospital of Guangzhou Medical University, Shaanxi Provincial People's Hospital, Henan Cancer Hospital, North China University of Science and Technology Affiliated Hospital, The Second Affiliated Hospital of Dalian Medical University, Second Hospital of Shanxi Medical University, The Second Affiliated Hospital of Harbin Medical University, Shenyang Sunshine Pharmaceutical Co., LTD., First Affiliated Hospital of Xinjiang Medical University, People's Hospital of Xinjiang Uygur Autonomous Region, Kashgar 1st People's Hospital, Xi'an Central Hospital, Beijing Public Health Foundation, Yuyao People's Hospital of Zhejiang Province | Previously Treated Primary Immune Thrombocytopenia | 02/24 | 07/24 | | |
NCT04845399: Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A |
|
|
| Completed | 3 | 101 | RoW | Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection | Zhengzhou Gensciences Inc, Jiangsu Gensciences lnc. | Hemophilia A | 06/21 | 06/21 | | |
NCT06142552: Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein |
|
|
| Recruiting | 3 | 120 | RoW | FRSW117, Recombinant human coagulation factor Ⅷ-Fc fusion protein for injection | Jiangsu Gensciences lnc. | Severe Hemophilia A | 01/26 | 09/26 | | |
NCT06312475: Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors |
|
|
| Recruiting | 3 | 51 | RoW | KN057 | Suzhou Alphamab Co., Ltd. | Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | 10/25 | 12/25 | | |
NCT06297655: A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A |
|
|
| Not yet recruiting | 3 | 60 | RoW | Recombinant human activated coagulation factor VIII for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Hemophilia A | 04/25 | 04/25 | | |
NCT06569108: Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors |
|
|
| Recruiting | 3 | 111 | RoW | KN057 | Suzhou Alphamab Co., Ltd. | Hemophilia A Without Inhibitor, Hemophilia B Without Inhibitor | 10/26 | 12/26 | | |
NCT05203679: Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug |
|
|
| Active, not recruiting | 3 | 32 | RoW | Single dose intravenous injection of BBM-H901 | Shanghai Belief-Delivery BioMed Co., Ltd | Hemophilia B | 04/24 | 06/28 | | |
CMML1-2, NCT06647862: IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia |
|
|
| Recruiting | 3 | 170 | RoW | IMM01, Timdarpacept, Azacitidine, Placebo | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Chronic Myelomonocytic Leukemia | 10/26 | 10/29 | | |
NCT06004856: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia |
|
|
| Recruiting | 3 | 195 | RoW | Orelabrutinib, Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Primary Immune Thrombocytopenia (ITP) | 12/25 | 04/26 | | |
NCT05709093: A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS) |
|
|
| Recruiting | 3 | 552 | RoW | Lemzoparlimab+Azacitidine (AZA), Azacitidine (AZA) | TJ Biopharma Co., Ltd. | Myelodysplastic Syndromes(MDS) | 03/27 | 03/27 | | |
NCT05232149: A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia |
|
|
| Recruiting | 2a/2b | 30 | RoW | Orelabrutinib( lower dose), Orelabrutinib( higher dose) | Beijing InnoCare Pharma Tech Co., Ltd. | Primary Immune Thrombocytopenia | 12/23 | 12/24 | | |
NCT05421429: KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia |
|
|
| Completed | 2 | 24 | RoW | KN057 doseⅠ, KN057 dose Ⅱ, KN057 dose Ⅲ | Suzhou Alphamab Co., Ltd. | Hemophilia | 01/24 | 01/24 | | |
| Recruiting | 2 | 25 | RoW | STSP-0601 for Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Hemophilia | 02/25 | 02/25 | | |
NCT04562870 / 2020-003809-60: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis |
|
|
| Active, not recruiting | 2 | 112 | Europe, US, RoW | Selinexor, Physician's Choice Treatment | Karyopharm Therapeutics Inc | Myelofibrosis | 01/25 | 01/25 | | |
|
|
HATCH, NCT04691141: A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS) |
|
|
| Terminated | 1/2 | 15 | RoW | ATG-016 | Shanghai Antengene Corporation Limited | Myelodysplastic Syndrome | 09/23 | 09/23 | | |
NCT06010953: SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment |
|
|
| Completed | 1/2 | 24 | RoW | SS109 | Jiangsu Gensciences lnc. | Male, Hemophilia A With Inhibitor, Hemophilia B With Inhibitor, Hemophilia | 05/24 | 05/24 | | |
NCT06245941: A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF) |
|
|
| Recruiting | 1/2 | 93 | RoW | TQ05105 tablets, TQB3909 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Myelofibrosis | 06/26 | 05/27 | | |
NCT05448599: A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS |
|
|
| Recruiting | 1/2 | 120 | RoW | 6MW3211 injection with Intravenous Infusion, infusion | Mabwell (Shanghai) Bioscience Co., Ltd. | Acute Myeloid Leukemia, Myelodysplastic Syndrome | 06/24 | 10/24 | | |
NCT06122831: A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF) |
|
|
| Recruiting | 1/2 | 92 | RoW | TQ05105 Tablets, TQB3617 Capsules | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Myelofibrosis | 12/26 | 04/27 | | |
NCT05651061: A Phase I of SS109 in Hemophilia A or and B With Inhibitors |
|
|
| Completed | 1 | 27 | RoW | SS109 | Jiangsu Gensciences lnc. | Hemophilia A With Inhibitor, Hemophilia B With Inhibitor, Factor VII Deficiency | 03/23 | 08/23 | | |
| Recruiting | 1 | 108 | RoW | GLB-001, GLB-C183-A-2 | Hangzhou GluBio Pharmaceutical Co., Ltd. | Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myeloid Malignancy | 12/26 | 12/27 | | |
| Gao, Guang xun |
NCT06245941: A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF) |
|
|
| Recruiting | 1/2 | 93 | RoW | TQ05105 tablets, TQB3909 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Myelofibrosis | 06/26 | 05/27 | | |
